Cargando…
The role of animal models in advancing amyloid-beta immunotherapy to the clinic
The amyloid-beta (Aβ) hypothesis of Alzheimer's disease (AD) causality is now well into its third decade and is finally entering a phase of rigorous clinical testing in numerous late stage clinical trials. The use of Aβ-based animal models of AD has been essential to the discovery and/or precli...
Autores principales: | Games, Dora, Seubert, Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949588/ https://www.ncbi.nlm.nih.gov/pubmed/20682084 http://dx.doi.org/10.1186/alzrt46 |
Ejemplares similares
-
Patient‐derived preclinical models to develop immunotherapies
por: Seoane, Joan
Publicado: (2023) -
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021) -
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
por: Zhou, Yixiu, et al.
Publicado: (2018) -
Management of Amyloid Cardiomyopathy in Resource-Constrained Settings: Challenges and Opportunities
por: Singh, Suvir, et al.
Publicado: (2021) -
Core Minimal Datasets to Advance Clinical Research for Priority Epidemic Diseases
por: Rojek, Amanda M, et al.
Publicado: (2020)